C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept

Arthritis and Rheumatism

Volumn 52, Issue 1, 2005, Pages 42-48

  Buch, Maya H ^a   Seto, Yohei ^a   Bingham, Sarah J ^a   Bejarano, Victoria ^a   Bryer, Domini ^a   White, Jo ^a   Emery, Paul ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; RETREATMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE;

EID: 12344317731     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20711     Document Type: Article

References (13)

1. Mebius RE. Organogenesis of lymphoid tissues. Nat Rev Immunol 2003;3:292-303.
2. Pepys MB. C-reactive protein: the role of an ancient protein in modern rheumatology. Clin Exp Rheumatol 1983;1:3-7.
3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
4. Emery P, Reginster JY, Appelboom T, Breedveld FC, Edelmann E, Kekow J, et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis: guidelines for prescribing TNF-α blockers in adults with RA. Rheumatology (Oxford) 2001;40:699-702.
5. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that includes twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
6. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
7. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
8. Van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
9. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33:305-15.
10. Van Vollenhoven RF, Klareskog L. Clinical responses to tumor necrosis factor α antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor α followup registry. Arthritis Rheum 2003;48:1500-3.
11. Buch MH, Conaghan PG, Quinn M, Bingham S, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin-α? Ann Rheum Dis 2004;63:1344-6. E-pub Mar 19.
12. Lipsky PE, Felson DT, Maini RN. Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: comment on the concise communication by Boers [letter]. Arthritis Rheum 2002;46:2817-8.
13. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.